

**Study Number:** I10482B  
**Test Type:** TOX  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Harlan Sprague Dawley

**M11: Spleen Cell Proliferative Response to Anti-CD3 Stimulation**  
**Test Compound:** N-Butylbenzenesulfonamide  
**CAS Number:** 3622-84-2

**Date Report Requested:** 11/20/2020  
**Time Report Requested:** 13:16:01  
**Lab:** Burleson Research Technologies

**Study Number:** I10482B  
**Study Gender:** Both  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.1.1

**Study Number:** I10482B

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Rat/Harlan Sprague Dawley

**M11: Spleen Cell Proliferative Response to Anti-CD3 Stimulation**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 11/20/2020

**Time Report Requested:** 13:16:01

**Lab:** Burleson Research Technologies

---

**F1 Males: Immunophenotyping**

---

**Treatment Groups (ppm)**

	<b>0</b>	<b>250</b>	<b>500</b>	<b>1000</b>	<b>15 mg/kg CPS</b>
CD3+ T-Cell (%)	53.9 ± 1.3 (12)	54.8 ± 1.3 (12)	53.2 ± 1.1 (11)	52.2 ± 1.1 (12)	80.8 ± 1.3 (8) **
Proliferating CD3+ T-cells (%)	20.9 ± 1.9 (12) **	19.3 ± 2.1 (12)	14.5 ± 1.7 (11) *	13.0 ± 1.8 (12) **	6.3 ± 1.0 (8) **
Proliferation Index	5771.8 ± 878.0 (12) *	6889.8 ± 787.9 (12)	4548.5 ± 828.7 (11)	4073.3 ± 747.9 (12)	737.8 ± 130.2 (8) **
Stimulation Index	17.3 ± 3.6 (12)	37.1 ± 9.0 (12)	23.5 ± 6.2 (11)	12.8 ± 3.4 (12)	5.8 ± 1.2 (8) **

---

**Study Number:** I10482B

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Rat/Harlan Sprague Dawley

**M11: Spleen Cell Proliferative Response to Anti-CD3 Stimulation**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 11/20/2020

**Time Report Requested:** 13:16:01

**Lab:** Burleson Research Technologies

---

**F1 Females: Immunophenotyping**

---

**Treatment Groups (ppm)**

	<b>0</b>		<b>250</b>		<b>500</b>		<b>1000</b>		<b>15 mg/kg CPS</b>	
CD3+ T-Cell (%)	52.6 ±	0.8 (12) *	50.6 ±	1.2 (12)	51.1 ±	1.2 (12)	48.5 ±	1.0 (12) *	81.6 ±	1.3 (8) **
Proliferating CD3+ T-cells (%)	17.7 ±	2.2 (12)	14.5 ±	2.4 (12)	18.2 ±	1.6 (12)	19.1 ±	2.4 (12)	7.6 ±	0.5 (8) **
Proliferation Index	6727.6 ±	1169.4 (12)	5525.3 ±	1252.3 (12)	7201.5 ±	1164.9 (12)	6712.8 ±	847.6 (12)	735.2 ±	67.7 (8) **
Stimulation Index	23.5 ±	3.7 (12)	19.9 ±	2.9 (12)	17.5 ±	1.6 (12)	17.5 ±	3.3 (12)	8.2 ±	1.5 (8) **

---

**Study Number:** I10482B

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Rat/Harlan Sprague Dawley

**M11: Spleen Cell Proliferative Response to Anti-CD3 Stimulation**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 11/20/2020

**Time Report Requested:** 13:16:01

**Lab:** Burleson Research Technologies

#### LEGEND

---

Data are displayed as mean  $\pm$  SEM (N) unless otherwise noted.

Proliferation Index is the product of the number of CD3+ / EdU+ T-cells multiplied by the mean fluorescent intensity of the CD3+ / EdU+ T-cell population.

Stimulation index is determined by dividing the Proliferation Index of cells stimulated by anti-CD3 by the Proliferation Index of non-stimulated cells.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

CPS = Cyclophosphamide

**\*\* END OF REPORT \*\***